Overall, our data point to an association between BCR-ABL1 gene expression and proliferative capacity in hematopoietic cell fractions with elevated/prominent separase proteolytic activity of CML patients without MMR (initial diagnosis) or after relapse. The gene discussed is ESPL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.